Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Roche (RHHBY) Announces Positive Results From PNH Studies
12:13pm, Monday, 12'th Jun 2023
Roche (RHHBY) crovalimab achieves disease control in paroxysmal nocturnal hemoglobinuria patients in the phase III COMMODORE 1 and COMMODORE 2 studies.
Growth in China Has to Be Domestic: Roche
01:41am, Monday, 12'th Jun 2023
David Roche, president and global strategist at Independent Strategy, explains what is the “gray zone”, asset allocation in China and his outlook for emerging markets. He speaks on Bloomberg Telev
U.S. debt ceiling deal is a 'democratic victory,' says David Roche
11:46pm, Sunday, 28'th May 2023
David Roche of Independent Strategy says the deal will allow borrowing to "go forward well into 2024," among other things.
Roche to present new data in blood cancers and solid tumours from its broad portfolio at ASCO 2023
01:00am, Friday, 26'th May 2023
Basel, 26 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and investigational medicines across ten cancer types at the 2023 American Society of Clinical Oncol
Roche, With Ocrevus And Fenebrutinib Advancement, Should Be Top MS Contender
07:36pm, Thursday, 25'th May 2023
It is expected that the market opportunity for disease-modifying therapies for MS will reach $29.8 billion in 2030; further projected that OCREVUS could generate sales of $6.3 billion by 2030. Roche H
10 A-Rated Dividend Aristocrats For The Ultimate High-Yield SWAN Portfolio
07:20am, Wednesday, 24'th May 2023
The debt ceiling crisis is coming down to the wire. We're possibly already out of time to prevent default and just don't know it. UBS estimates a short default could create a 20% bear market and a one
Why Shares of Rain Oncology Are Plummeting Today
03:15pm, Monday, 22'nd May 2023
Rain Oncology has milademetan in several trials. The oral therapy didn't show a big advantage over the current standard of care in treating dedifferentiated liposarcoma.
Roche's (RHHBY) MS Drug Meets Goals in the Phase II Study
12:47pm, Wednesday, 17'th May 2023
Roche's (RHHBY) investigational oral fenebrutinib meets its primary and secondary endpoints in the phase II FENopta study.
3 Stocks That Are Reshaping the Future
11:04am, Tuesday, 16'th May 2023
Investors can find growth plays in many corners of the stock market, but a smart play would be looking for the stocks reshaping the future. These are companies at the forefront of a burgeoning trend
Roche (RHHBY) Q1 Revenues Decline on Lower COVID-19 Test Sales
10:40am, Wednesday, 26'th Apr 2023
Roche's (RHHBY) performance in first-quarter 2023 is pretty ho-hum as COVID-19-test sales continue to decline.
Pharma Behemoths GSK, Roche Outplay Covid Declines To Beat Quarterly Calls
09:16am, Wednesday, 26'th Apr 2023
GSK and Roche both outplayed declining Covid-related sales in the first quarter to beat Wall Street's earnings expectations. The post Pharma Behemoths GSK, Roche Outplay Covid Declines To Beat Quarter
Roche sees sales drop on lower demand for COVID-19 tests, but backs view
01:43am, Wednesday, 26'th Apr 2023
Roche Holding AG on Wednesday posted a decline in sales for the first quarter as its diagnostics division suffered from significantly lower demand for Covid-19 tests, and backed its outlook for the ye
Roche (RHHBY) Polivy Combination for DLBCL Gets Full Approval
03:13pm, Thursday, 20'th Apr 2023
Roche (RHHBY) gets full approval for Polivy (polatuzumab vedotin-piiq) in combination with Rituxan, cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of adult patients who have pr
Roche (RHHBY) Announces Data on Tecentriq Combo for HCC
02:26pm, Monday, 17'th Apr 2023
Roche's (RHHBY) new data from the late-stage IMbrave050 study reveals that the combination of Tecentriq and Avastin reduces the risk of cancer relapsing in people with certain types of adjuvant liver
Roche's Tecentriq shows further good survival rates as cancer treatment
01:20am, Monday, 17'th Apr 2023
Roche Holding AG said Sunday that its tecentriq immunotherapy drug showed further positive results in an advanced study, demonstrating significant improvement in recurrence-free survival in patients.
